Racial and Ethnic Differences in the Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System
Julio Lamprea-Montealegre, MD, PhD, MPH
Justin List, MD, MAR, MSc, FACP
Seminar date: 1/11/2023
Description: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) have changed the approach to the management of type 2 diabetes because both classes have cardiovascular and kidney protective effects. This Focus on Health Equity and Action Cyberseminar session will highlight recent research that found that among patients with type 2 diabetes in the Veterans Health Administration system, prescription of SGLT2i and GLP-1 RA was low overall, and there were differences in prescribing by race and ethnicity. The session will also discuss possible opportunities to intervene to address this disparity across the Veterans Health Administration.
Intended audience: Researchers, clinicians, care coordinators, policy makers, educators, data analysts, Veteran stakeholders and representatives of vulnerable Veteran groups who are interested in understanding and/or promoting equitable health among all Veterans.